|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/16 | (2006.01) |
| A61K 9/1647 | (2013.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61K 9/1629 | (2013.01) | ||
| A61K 47/34 | (2017.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61K 31/551 | (2006.01) | ||
| A61K 31/551 | (2013.01) | ||
| A61P 25/18 | (2006.01) | ||
| A61K 9/0019 | (2013.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61K 31/00 | (2013.01) |
| (11) | Number of the document | 3352735 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16775424.1 |
| Date of filing the European patent application | 2016-09-21 | |
| (97) | Date of publication of the European application | 2018-08-01 |
| (45) | Date of publication and mention of the grant of the patent | 2023-08-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/052757 |
| Date | 2016-09-21 |
| (87) | Number | WO 2017/053346 |
| Date | 2017-03-30 |
| (30) | Number | Date | Country code |
| 201562221290 P | 2015-09-21 | US |
| (72) |
SMITH, Mark, Alan , US
CLAASSEN-PUNT, Carine , NL
|
| (73) |
Teva Pharmaceuticals International GmbH ,
Schlüsselstrasse 12, 8645 Jona,
CH
|
| (54) | SUSTAINED RELEASE OLANZAPINE FORMULATIONS |
| SUSTAINED RELEASE OLANZAPINE FORMULATIONS |